• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥沙利铂生物转化产物的高效液相色谱分离

High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.

作者信息

Luo F R, Yen T Y, Wyrick S D, Chaney S G

机构信息

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill 27599, USA.

出版信息

J Chromatogr B Biomed Sci Appl. 1999 Mar 19;724(2):345-56. doi: 10.1016/s0378-4347(98)00565-9.

DOI:10.1016/s0378-4347(98)00565-9
PMID:10219677
Abstract

A novel single reversed-phase HPLC system was developed for separating oxaliplatin and its biotransformation products formed in rat plasma. The major stable biotransformation products of oxaliplatin formed in rat plasma were identified as Pt(dach)(Cys)2, Pt(dach)(Met) and free dach. The minor biotransformation products Pt(dach)Cl2, Pt(dach)(GSH) and Pt(dach)(GSH)2 could also be resolved from other Pt-dach complexes. Among these biotransformation products, the identification of Pt(dach)(Met) was further confirmed by LC-ESI-MS, and the identification of Pt(dach)(Cys)2, Pt(dach)(GSH), Pt(dach)(GSH)2 and free dach was confirmed by atomic absorption and double isotope labeling. This HPLC technique should prove useful for separating and identifying the biotransformation products of Pt-dach drugs such as oxaliplatin, ormaplatin and Pt(dach)(mal) in biological fluids. This will allow a more complete characterization of the pharmacokinetics and biotransformations of these Pt-dach drugs, which should in turn lead to a better understanding of the mechanisms leading to their toxicity and efficacy.

摘要

开发了一种新型的反相高效液相色谱系统,用于分离奥沙利铂及其在大鼠血浆中形成的生物转化产物。在大鼠血浆中形成的奥沙利铂的主要稳定生物转化产物被鉴定为Pt(dach)(Cys)2、Pt(dach)(Met)和游离的dach。次要生物转化产物Pt(dach)Cl2、Pt(dach)(GSH)和Pt(dach)(GSH)2也能与其他Pt-dach配合物分离。在这些生物转化产物中,Pt(dach)(Met)的鉴定通过液相色谱-电喷雾电离质谱进一步得到证实,而Pt(dach)(Cys)2、Pt(dach)(GSH)、Pt(dach)(GSH)2和游离dach的鉴定则通过原子吸收和双同位素标记得到证实。这种高效液相色谱技术对于分离和鉴定生物流体中Pt-dach类药物(如奥沙利铂、奥马铂和Pt(dach)(mal))的生物转化产物应是有用的。这将有助于更全面地表征这些Pt-dach类药物的药代动力学和生物转化过程,进而有助于更好地理解导致其毒性和疗效的机制。

相似文献

1
High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.奥沙利铂生物转化产物的高效液相色谱分离
J Chromatogr B Biomed Sci Appl. 1999 Mar 19;724(2):345-56. doi: 10.1016/s0378-4347(98)00565-9.
2
Biotransformations of oxaliplatin in rat blood in vitro.奥沙利铂在大鼠血液中的体外生物转化。
J Biochem Mol Toxicol. 1999;13(3-4):159-69. doi: 10.1002/(sici)1099-0461(1999)13:3/4<159::aid-jbt6>3.0.co;2-c.
3
Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.大鼠单次静脉推注后奥沙利铂与奥马铂的药代动力学及生物转化比较
Cancer Chemother Pharmacol. 1999;44(1):19-28. doi: 10.1007/s002800050940.
4
Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.利用大鼠背根神经节体外植体培养模型比较奥沙利铂、奥马铂及其生物转化产物的神经毒性。
Cancer Chemother Pharmacol. 1999;44(1):29-38. doi: 10.1007/s002800050941.
5
Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.奥沙利铂的生物转化及药代动力学:一项旨在确定其与神经毒性可能关系的初步研究。
Anticancer Res. 2002 Jul-Aug;22(4):2301-9.
6
Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.奥沙利铂在人结肠癌细胞中的细胞毒性、细胞摄取及细胞生物转化
Oncol Res. 1998;10(11-12):595-603.
7
In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
Cancer Res. 1990 Aug 1;50(15):4539-45.
8
Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.奥马铂在费希尔344大鼠体内的器官特异性生物转化
Cancer Chemother Pharmacol. 1995;36(5):439-47. doi: 10.1007/BF00686194.
9
Early biotransformations of oxaliplatin after its intravenous administration to cancer patients.奥沙利铂静脉注射给癌症患者后的早期生物转化
Drug Metab Dispos. 2000 Nov;28(11):1379-84.
10
Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.
Cancer Chemother Pharmacol. 1991;27(5):335-41. doi: 10.1007/BF00688854.

引用本文的文献

1
Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention.设计一种用于预防癌症的黏附性化疗贴片以消融口腔发育异常。
Small. 2022 Jun;18(25):e2201561. doi: 10.1002/smll.202201561. Epub 2022 May 19.
2
Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats.超高效液相色谱-串联质谱法测定奥沙利铂:在大鼠药代动力学及舌组织分布研究中的应用
Pharmaceuticals (Basel). 2021 Dec 31;15(1):52. doi: 10.3390/ph15010052.
3
Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer.
载奥沙利铂纳米粒的制备、优化及其在非小细胞肺癌中的体外评价。
Daru. 2020 Dec;28(2):673-684. doi: 10.1007/s40199-020-00374-5. Epub 2020 Oct 22.
4
Synthesis, characterization and in vitro antitumor activity of platinum(II) oxalato complexes involving 7-azaindole derivatives as coligands.以7-氮杂吲哚衍生物作为配体的草酸铂(II)配合物的合成、表征及体外抗肿瘤活性
Molecules. 2014 Jul 25;19(8):10832-44. doi: 10.3390/molecules190810832.
5
Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model.米立铂碘油混悬乳剂对兔 VX2 肝癌的抑瘤作用
Jpn J Radiol. 2013 Oct;31(10):662-7. doi: 10.1007/s11604-013-0231-7. Epub 2013 Jul 5.
6
Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.德博 0507 主要在 HCT116 细胞中形成二胺环戊烷-Pt-d(GpG)和-d(ApG)DNA 加合物。
Cancer Chemother Pharmacol. 2012 Mar;69(3):665-77. doi: 10.1007/s00280-011-1744-3. Epub 2011 Oct 4.
7
Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.奥沙利铂在大鼠体内的药代动力学和毒代动力学:应用毒性因子解释奥沙利铂和其他铂类抗肿瘤衍生物引起的肾毒性和骨髓抑制的差异。
Pharm Res. 2010 Sep;27(9):1893-9. doi: 10.1007/s11095-010-0189-4. Epub 2010 Jun 15.
8
Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis.将米铂悬浮于油性淋巴造影剂中进行肝内动脉给药,可通过诱导铂 - DNA加合物形成和大量细胞凋亡来抑制植入大鼠肝脏的肿瘤生长。
Cancer Chemother Pharmacol. 2009 Aug;64(3):473-83. doi: 10.1007/s00280-008-0895-3. Epub 2008 Dec 24.
9
Oxaliplatin: pharmacokinetics and chronopharmacological aspects.奥沙利铂:药代动力学与时辰药理学方面
Clin Pharmacokinet. 2000 Jan;38(1):1-21. doi: 10.2165/00003088-200038010-00001.